{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=5", "query": { "intervention": "Daily dosing", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 3690, "total_pages": 369, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T12:48:47.990Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00487825", "title": "Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Canakinumab (investigational)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 78, "start_date": "2007-03", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 17, "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487825" }, { "nct_id": "NCT05967689", "title": "A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" }, { "name": "CYP Cocktail", "type": "DRUG" }, { "name": "Transporter Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2023-07-31", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05967689" }, { "nct_id": "NCT01946074", "title": "A Study of ABT-165 in Subjects With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "ABT-165", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 101, "start_date": "2013-08-08", "completion_date": "2022-09-28", "has_results": false, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946074" }, { "nct_id": "NCT07121946", "title": "This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma Refractory/ Relapsed", "DLBCL - Diffuse Large B Cell Lymphoma", "Mantle Cell Lymphoma (MCL)", "Follicular Lymphoma ( FL)", "Marginal Zone Lymphoma (MZL)" ], "interventions": [ { "name": "LTZ-301", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "LTZ Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-01-29", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 6, "location_summary": "Duarte, California • St Louis, Missouri • Buffalo, New York + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07121946" }, { "nct_id": "NCT02287233", "title": "A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "AML" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 94, "start_date": "2014-12-31", "completion_date": "2021-08-10", "has_results": true, "last_update_posted_date": "2022-08-29", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 5, "location_summary": "Kansas City, Kansas • New York, New York • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287233" }, { "nct_id": "NCT02396368", "title": "A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)" ], "interventions": [ { "name": "Tasquinimod", "type": "DRUG" }, { "name": "Radium 223", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2015-03", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02396368" }, { "nct_id": "NCT00619879", "title": "Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia, Myelogenous, Chronic", "Leukemia, Lymphoblastic, Acute", "Leukemia, Myelogenous, Acute", "Myeloproliferative-Myelodysplastic Diseases", "Lymphoma, Malignant" ], "interventions": [ { "name": "Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients", "type": "DRUG" }, { "name": "Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies", "type": "DRUG" }, { "name": "Hematopoietic Progenitor Cell Transplantation (HPCT)", "type": "OTHER" }, { "name": "CNS radiation treatment for ALL with prior CNS disease patients", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 81, "start_date": "2007-03-26", "completion_date": "2019-02-07", "has_results": false, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619879" }, { "nct_id": "NCT05734196", "title": "The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency", "Autosomal Recessive Hypophosphatemic Rickets", "Generalized Arterial Calcification of Infancy", "ATP-Binding Cassette Subfamily C Member 6 Deficiency", "Pseudoxanthoma Elasticum" ], "interventions": [ { "name": "INZ-701", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inozyme Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "1 Year", "sex": "ALL", "summary": "Up to 1 Year" }, "enrollment_count": 9, "start_date": "2023-06-25", "completion_date": "2026-09-29", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 3, "location_summary": "San Diego, California • Columbus, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05734196" }, { "nct_id": "NCT01081132", "title": "Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention-Deficit/Hyperactivity Disorder" ], "interventions": [ { "name": "Extended-release Guanfacine Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 314, "start_date": "2011-09-19", "completion_date": "2013-05-16", "has_results": true, "last_update_posted_date": "2021-06-28", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 54, "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Spring Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01081132" }, { "nct_id": "NCT04676399", "title": "Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Chronic Pain", "Hypertension", "Diuretics Drug Reactions", "SCS" ], "interventions": [ { "name": "Hydrochlorothiazide 12.5mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "40 Years to 79 Years" }, "enrollment_count": 36, "start_date": "2022-02-08", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-26T12:48:47.990Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04676399" } ] }